Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy.

Clinical laboratory - 1 Jan 2015

Lin Jiayao, Zhang Yu, Zhou Houguang, Wang Xinqing, Wang Wenwen

Abstract excerpt

BACKGROUND: There is well-known inter-individual variability in the cholesterol-lowering effect of statins. However, inter-individual variability in response to rosuvastatin treatment in subjects with hypercholesterolemia has not been clearly established. This study aimed to evaluate the associations of CYP2C9 genetic polymorphism with the efficacy and safety of rosuvastatin in Chinese patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Combined Modality Therapy
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diet, Fat-Restricted

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hyperlipidemias

Share to Inactivation, Metabolic

Share to Individuality

Share to Rosuvastatin Calcium

Source

Identifiers

PMID: 26554252
DOI: 10.7754/clin.lab.2015.150123

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy.PMID 26554252Read ↗

Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients.Semantic proximity Read ↗

Pharmacogenomic analysis of low-density lipoprotein receptor 3' untranslated region genetic variants influencing rosuvastatin efficacy in Chinese dyslipidemia patients.Semantic proximity Read ↗

Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemiaSemantic proximity Read ↗

Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.Semantic proximity Read ↗

Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.Semantic proximity Read ↗

The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study.Semantic proximity Read ↗

The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin.Semantic proximity Read ↗

The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.Semantic proximity Read ↗

The frequency of rs2231142 in ABCG2 among Asian subgroups: implications for personalized rosuvastatin dosing.Semantic proximity Read ↗

Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects.Semantic proximity Read ↗

Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.